Prevention strategies against the human papillomavirus: the effectiveness of vaccination (Q28253369)

Cervical cancer and sexual lifestyle: a systematic review of health education interventions targeted at women

Europe PubMed Central

title

Prevention strategies against the human papillomavirus: the effectiveness of vaccination (English)

0 references

author name string

M Stanley

series ordinal

1

0 references

language of work or name

English

0 references

publication date

November 2007

0 references

published in

Gynecologic Oncology

0 references

volume

107

0 references

issue

2 Suppl 1

0 references

page(s)

S19-23

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.068

Cost-effectiveness analyses of human papillomavirus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.068

Condom use and the risk of genital human papillomavirus infection in young women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.068

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.068

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.068

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.068

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.068

Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.068

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.068

Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.068

Cost-effectiveness of a potential vaccine for human papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.068

Evaluating human papillomavirus vaccination programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.068

CHAPTER 10 A public health approach to cervical cancer control: Considerations of screening and vaccination strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.068

Model for assessing human papillomavirus vaccination strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.068

Impact of HPV testing, HPV vaccine development, and changing screening frequency on national Pap test volume: projections from the National Health Interview Survey (NHIS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.068

Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.07.068